Abstract:
Pain, pyrexia and inflammation cause unnecessary discomfort, suffering and also
lower productivity of the victims. Conventional drugs for these conditions are
expensive, not easily available and have adverse side effects. There is therefore
need to develop alternative therapeutic agents, such as medicinal plant
derivatives, that are cheaper and have lesser side effects. Terminalia brownii is
used in traditional medicine to treat pain, pyrexia, inflammation but there is no
scientific evidence to confirm these ethno-medicinal claims. The present study
therefore tested for the anti-nociceptive, antipyretic and anti-inflammatory
properties of methanolic bark extracts of T brownii in Rattus novegicus. The
plant samples sourced from Kitui County, Kenya were dried and milled at
Kenyatta University Biochemistry department laboratory. Adult male Wistar rats
(R. novegicus), 2-3 months old, weighing 140-180g were divided into six groups
of 5 rats each scheduled for different treatments; normal, negative and positive
controls and three experimental groups (50, 100 and 150mglkg bw extract).
Formalin-induced pain, turpentine oil-induced pyrexia and carrageenan-induced
paw edema were used to assess the anti nociceptive, antipyretic and antiinflammatory
properties of the extract, respectively. The antinociceptive and antiinflammatory
activities of the extract were compared to those of diclofenac while
the antipyretic activity of the extract was compared to that of aspirin. The
phytochemical secondary metabolites tested for include alkaloids, cardiac
glycosides, flavonoids, phenols, saponins, steroids and terpenoids. T brownii
methanolic bark extract demonstrated significant antinociceptive, antipyretic and
anti-inflammatory effects in a dose-dependent manner. The extract at the dose
level of 150mglkg bw exhibited the highest antinociceptive, antipyretic and antiinflammatory
activities and its activities were comparable to those of the
respective reference drugs. The methanolic bark extracts of T brownii reduced
the paw licking time by between 4.62%-44.96% (pSO.05) in the early phase and
35.77%-58.89% (pSO.05) in the late phase. Diclofenac on the other hand reduced
the paw licking time by 44.79% in the early phase and 55.33% in the late phase.
The extract reduced the elevated rectal temperatures by between 1.15%-4.38%
(pSO.05) while aspirin reduced by between 0.00%-4.85%. The extract reduced the
inflamed paw diameter by between 1.57%-20.41 % (pSO.05) while diclofenac
reduced by between 11.12%-25.33%. Phytochemical screening of the extract
indicated the presence of alkaloids, cardiac glycosides, flavonoids, phenols,
saponins, steroids and terpenoids. The present study therefore demonstrated the
antinociceptive, antipyretic and anti-inflammatory properties of methanolic bark
extracts of T brownii hence providing a basis for further research that may result
in pure compounds that can be advanced into drug discovery.